Systems pharmacology identifies drug targets for Stargardt disease-Associated retinal degeneration

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5119-5134

  Chen, Yu ^a   Palczewska, Grazyna ^b   Mustafi, Debarshi ^a   Golczak, Marcin ^a   Dong, Zhiqian ^b   Sawada, Osamu ^a   Maeda, Tadao ^a   Maeda, Akiko ^a   Palczewski, Krzysztof ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Polgenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 (2 PYRIDINYL) 1 PIPERAZINYL]METHYL] 1H BENZIMIDAZOLE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 INDOLECARBOXYLIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; AGOMELATINE; ALPHA 2A ADRENERGIC RECEPTOR; CYPROHEPTADINE; DOX; DOXAZOSIN; ELTOPRAZINE; FEXOFENADINE; G PROTEIN COUPLED RECEPTOR; GUANABENZ; GUANFACINE; LOF; LOFEXIDINE; N (2 HYDROXYCYCLOPENTYL) 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXAMIDE; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; NEFAZODONE; PHENOXYBENZAMINE; PHENTOLAMINE; PIZOTIFEN; PRAZOSIN; RS 39604; SEROTONIN; SGS 518 OXALATE; TAMSULOSIN; TOLTERODINE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; EYE PROTECTION; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTORECEPTOR CELL; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RETINA DEGENERATION; RETINA MACULA DEGENERATION; SIGNAL TRANSDUCTION; STARGARDT DISEASE;

ADENINE; ADENYLATE CYCLASE; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ALCOHOL OXIDOREDUCTASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXAZOSIN; DRUG EVALUATION, PRECLINICAL; GUANABENZ; HUMANS; LIGHT; MACACA FASCICULARIS; MACULAR DEGENERATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; PHOTORECEPTOR CELLS, VERTEBRATE; REACTIVE OXYGEN SPECIES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 84890086440     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69076     Document Type: Article

References (88)

1. Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11):745-755
2. Ku CS, et al. Exome versus transcriptome sequencing in identifying coding region variants. Expert Rev Mol Diagn. 2012;12(3):241-251
3. De Matteis MA, Luini A. Mendelian disorders of membrane trafficking. N Engl J Med. 2011;365(10):927-938
4. Hubner N, et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 2005;37(3):243-253
5. Dermitzakis ET. Cellular genomics for complex traits. Nat Rev Genet. 2012;13(3):215-220
6. Cooper GM, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet. 2011;12(9):628-640
7. Zhou K, Pearson ER. Insights from genome-wide association studies of drug response. Annu Rev Pharmacol Toxicol. 2013;53:299-310
8. Kleeberger SR, Peden D. Gene-environment interactions in asthma and other respiratory diseases. Annu Rev Med. 2005;56:383-400
9. de Krom M, Bauer F, Collier D, Adan RA, la Fleur SE. Genetic variation and effects on human eating behavior. Annu Rev Nutr. 2009;29:283-304
10. Gutiu IA, Andries A, Mircioiu C, Radulescu F, Georgescu AM, Cioaca D. Pharmacometabonomics, pharmacogenomics and personalized medicine. Rom J Intern Med. 2010;48(2):187-191
11. Camilleri M. The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2012;9(3):173-184
12. Stallmeyer B, et al. Mutational spectrum in the Ca(2+) - activated cation channel gene TRPM4 in patients with cardiac conductance disturbances. Hum Mutat. 2012;33(1):109-117
13. Tremblay J, Hamet P. Genetics of pain, opioids, and opioid responsiveness. Metabolism. 2010; 59(suppl 1):S5-S8
14. Allerheiligen SR. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther. 2010; 88(1):135-137
15. Hansen J, Zhao S, Iyengar R. Systems pharmacology of complex diseases. Ann N Y Acad Sci. 2011;1245:E1-E5
16. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-521
17. van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov. 2005; 4(12):961-967
18. Bai JP, Abernethy DR. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu Rev Pharmacol Toxicol. 2013;53:451-473
19. Kassahn KS, Waddell N, Grimmond SM. Sequencing transcriptomes in toto. Integr Biol (Camb). 2011; 3(5):522-528
20. Costa V, Angelini C, De Feis I, Ciccodicola A. Uncovering the complexity of transcriptomes with RNA-Seq. J Biomed Biotechnol. 2010;2010:853916
21. Provis JM. Development of the primate retinal vasculature. Prog Retin Eye Res. 2001;20(6):799-821
22. Fruttiger M. Development of the retinal vasculature. Angiogenesis. 2007;10(2):77-88
23. Travis GH, Golczak M, Moise AR, Palczewski K. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol. 2007;47:469-512
24. Mustafi D, Engel AH, Palczewski K. Structure of cone photoreceptors. Prog Retin Eye Res. 2009; 28(4):289-302
25. Palczewski K. Chemistry and biology of vision. J Biol Chem. 2012;287(3):1612-1619
26. Castro Lima V, Rodrigues EB, Nunes RP, Sallum JF, Farah ME, Meyer CH. Simultaneous confocal scanning laser ophthalmoscopy combined with high-resolution spectral-domain optical coherence tomography: a review. J Ophthalmol. 2011;2011:743670
27. Costa RA, et al. Retinal assessment using optical coherence tomography. Prog Retin Eye Res. 2006; 25(3):325-353
28. Gabriele ML, et al. Three dimensional optical coherence tomography imaging: advantages and advances. Prog Retin Eye Res. 2010;29(6):556-579
29. Imanishi Y, Batten ML, Piston DW, Baehr W, Palczewski K. Noninvasive two-photon imaging reveals retinyl ester storage structures in the eye. J Cell Biol. 2004;164(3):373-383
30. Hunter JJ, et al. Images of photoreceptors in living primate eyes using adaptive optics two-photon ophthalmoscopy. Biomed Opt Express. 2010;2(1):139-148
31. Maeda A, et al. Primary amines protect against retinal degeneration in mouse models of retinopathies. Nat Chem Biol. 2012;8(2):170-178
32. Palczewska G, et al. Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyes. Nature Medicine. 2010;16(12):1444-1449
33. Orban T, Palczewska G, Palczewski K. Retinyl ester storage particles (retinosomes) from the retinal pigmented epithelium resemble lipid droplets in other tissues. J Biol Chem. 2011;286(19):17248-17258
34. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol. 2010;703:105-125
35. Kiser PD, Golczak M, Maeda A, Palczewski K. Key enzymes of the retinoid (visual) cycle in vertebrate retina. Biochim Biophys Acta. 2012;1821(1):137-151
36. Maeda A, Golczak M, Maeda T, Palczewski K. Limited roles of Rdh8, Rdh12, and Abca4 in alltrans- retinal clearance in mouse retina. Invest Ophthalmol Vis Sci. 2009;50(11):5435-5443
37. Maeda A, Maeda T, Golczak M, Palczewski K. Retinopathy in mice induced by disrupted all-trans-retinal clearance. J Biol Chem. 2008;283(39):26684-26693
38. Maeda A, et al. Involvement of all-trans-retinal in acute light-induced retinopathy of mice. J Biol Chem. 2009;284(22):15173-15183
39. Chen Y, et al. Mechanism of all-trans-retinal toxicity with implications for stargardt disease and age-related macular degeneration. J Biol Chem. 2012; 287(7):5059-5069
40. Lem J, et al. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci U S A. 1999;96(2):736-741
41. Kohno H, et al. Photoreceptor proteins initiate microglial activation via Toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal. J Biol Chem. 2013;288(21):15326-15341
42. Buck K, Voehringer P, Ferger B. The α(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopaminelesioned rats. J Neurochem. 2010;112(2):444-452
43. Jeon CJ, Strettoi E, Masland RH. The major cell populations of the mouse retina. J Neurosci. 1998; 18(21):8936-8946
44. Sparrow JR, Wu Y, Kim CY, Zhou J. Phospholipid meets all-trans-retinal: the making of RPE bisretinoids. J Lipid Res. 2010;51(2):247-261
45. Cideciyan AV, et al. ABCA4 disease progression and a proposed strategy for gene therapy. Hum Mol Genet. 2009;18(5):931-941
46. Sparrow JR, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012; 31(2):121-135
47. Mustafi D, Maeda T, Kohno H, Nadeau JH, Palczewski K. Inflammatory priming predisposes mice to age-related retinal degeneration. J Clin Invest. 2012;122(8):2989-3001
48. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75(1):26-39
49. von Lintig J, Kiser PD, Golczak M, Palczewski K. The biochemical and structural basis for trans-tocis isomerization of retinoids in the chemistry of vision. Trends Biochem Sci. 2010;35(7):400-410
50. Kiser PD, Palczewski K. Membrane-binding and enzymatic properties of RPE65. Prog Retin Eye Res. 2010;29(5):428-442
51. Yu DY, Cringle SJ. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res. 2001;20(2):175-208
52. Lange CA, Bainbridge JW. Oxygen sensing in retinal health and disease. Ophthalmologica. 2012; 227(3):115-131
53. Bazan NG. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 2006;29(5):263-271
54. Chertov AO, et al. Roles of glucose in photoreceptor survival. J Biol Chem. 2011;286(40):34700-34711
55. Jones BW, et al. Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol. 2003;464(1):1-16
56. McBee JK, Palczewski K, Baehr W, Pepperberg DR.Confronting complexity: the interlink of phototransduction and retinoid metabolism in the vertebrate retina. Prog Retin Eye Res. 2001;20(4):469-529
57. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2012;9(1):44-53
58. Nguyen-Legros J, Hicks D. Renewal of photoreceptor outer segments and their phagocytosis by the retinal pigment epithelium. Int Rev Cytol. 2000; 196:245-313
59. Kevany BM, Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda). 2010;25(1):8-15
60. Fong WG, Tsilfidis C. Retinal degeneration and cellular suicide. Adv Exp Med Biol. 2012;723:207-214
61. Mitter SK, et al. Autophagy in the retina: a potential role in age-related macular degeneration. Adv Exp Med Biol. 2012;723:83-90
62. Grimm C, Wenzel A, Williams T, Rol P, Hafezi F, Reme C. Rhodopsin-mediated blue-light damage to the rat retina: effect of photoreversal of bleaching. Invest Ophthalmol Vis Sci. 2001;42(2):497-505
63. Wilt TJ, MacDonald R. Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clin Interv Aging. 2006;1(4):389-401
64. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5(9):1957-1964
65. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol. 1998;159(6):1810-1815
66. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-161
67. Roehrborn CG. Efficacy of α-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. 2009;11(suppl 1):S1-S8
68. Suzuki F, et al. Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes. Br J Pharmacol. 2002;135(3):600-608
69. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci. 2007;24(5):745-756
70. Jerie P. Clinical experience with guanfacine in longterm treatment of hypertension. Br J Clin Pharmacol. 1980;10(suppl 1):37S-47S
71. Jerie P. Clinical experience with guanfacine in longterm treatment of hypertension. Part 2: adverse reactions to guanfacine. Br J Clin Pharmacol. 1980; 10(suppl 1):157S-164S
72. Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone- precipitated withdrawal in opioid-dependent humans. Addiction. 2003;98(4):427-439
73. Abdel-Majid RM, Tremblay F, Baldridge WH. Localization of adenylyl cyclase proteins in the rodent retina. Brain Res Mol Brain Res. 2002;101(1-2):62-70
74. Cao P, et al. Light-sensitive coupling of rhodopsin and melanopsin to G(i/o) and G(q) signal transduction in Caenorhabditis elegans. FASEB J. 2012;26(2):480-491
75. Eglen RM, et al. RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br J Pharmacol. 1993;110(1):119-126
76. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. Mol Vis. 2006;12:1040-1047
77. Michaels KV, et al. Serotonin receptor expression in the rodent retina. Presented at: ARVO 2011 Visionary Genomics; May 1-5, 2011; Fort Lauderdale, Florida, USA. Abstract 919/A111
78. Collier RJ, et al. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci. 2011;52(5):2118-2126
79. Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615-649
80. Grimm C, Wenzel A, Hafezi F, Yu S, Redmond TM, Reme CE. Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. Nat Genet. 2000;25(1):63-66
81. Hao W, et al. Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat Genet. 2002;32(2):254-260
82. Jacobson SG, McInnes RR. Blinded by the light. Nat Genet. 2002;32(2):215-216
83. Mustafi D, et al. Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. FASEB J. 2011;25(9):3157-3176
84. Huber G, et al. Spectral domain optical coherence tomography in mouse models of retinal degeneration. Invest Ophthalmol Vis Sci. 2009;50(12):5888-5895
85. Maeda A, et al. Role of photoreceptor-specific retinol dehydrogenase in the retinoid cycle in vivo. J Biol Chem. 2005;280(19):18822-18832
86. Erceg M, Cindric M, Pozaic Frketic L, Vertzoni M, Cetina-Cizmek B, Reppas C. A LC-MS-MS method for determination of low doxazosin concentrations in plasma after oral administration to dogs. J Chromatogr Sci. 2010;48(2):114-119
87. Harkins JD, et al. The detection and biotransformation of guanabenz in horses: a preliminary report. Vet Ther. 2003;4(2):197-209
88. Palczewski K, Orban T. From atomic structures to neuronal functions of g protein-coupled receptors. Annu Rev Neurosci. 2013;36:139-164